13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839435
Total reported value
$1.1B
$1.1B
44 檔
28.4%
As reported in its official Q2 2024 Form 13F filing, Octagon Capital Advisors LP's tracked investment portfolio stood at $1.1B with 44 total positions.
During Q2 2024, Octagon Capital Advisors LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 19.48% | — | +7.45% | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 9.48% | — | -21.03% | |
| 3 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 7.10% | -1.94% | +26.51% | |
| 4 | GPCR | Structure Therapeutics Inc | Stock-Other | 7.04% | — | +125.04% | |
| 5 | DYN | Dyne Therapeutics Inc | Stock-Other | 6.55% | — | -5.00% | |
| 6 | AVBP | Arrivent Biopharma Inc | Stock-Other | 5.26% | +1.12% | -7.23% | |
| 7 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.31% | — | -20.00% | |
| 8 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 3.47% | — | +20.49% | |
| 9 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.33% | -3.30% | EXIT | |
| 10 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.75% | — | — | |
| 11 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.61% | -1.14% | — | |
| 12 | CATX | Perspective Therapeutics Inc | Stock-Other | 2.48% | -0.37% | EXIT | |
| 13 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.44% | — | — | |
| 14 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.69% | — | — | |
| 15 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.61% | +1.55% | +50.90% | |
| 16 | EYPT | Eyepoint Inc | Stock-Other | 1.50% | — | — | |
| 17 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.46% | -3.09% | EXIT | |
| 18 | GOSS | Gossamer Bio Inc | Stock-Other | 1.30% | -0.17% | — | |
| 19 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.27% | — | — | |
| 20 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 1.26% | — | -9.73% | |
| 21 | RGLS | Regulus Therapeutics Inc | Stock-Other | 1.20% | — | — | |
| 22 | ✓ | Stock-Other | 1.11% | — | +133.33% | ||
| 23 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.10% | — | +9.09% | |
| 24 | ANTX | An2 Therapeutics Inc | Stock-Other | 1.09% | — | +191.95% | |
| 25 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.04% | — | -16.66% | |
| 26 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.03% | — | -42.59% | |
| 27 | PEPG | Pepgen Inc | Stock-Other | 0.94% | — | — | |
| 28 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.87% | — | +59.29% | |
| 29 | CYBNEUR | Cybin Inc | Stock-Other | 0.79% | — | — | |
| 30 | IPSC | Century Therapeutics Inc | Stock-Other | 0.53% | — | +146.97% | |
| 31 | ✓ | Reneo Pharmaceuticals Inc | Stock-Other | 0.53% | — | — | |
| 32 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.53% | — | -44.13% | |
| 33 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.40% | — | — | |
| 34 | PSTXUSD | Poseida Therapeutics Inc | Stock-Other | 0.34% | — | — | |
| 35 | ✓ | Elevation Oncology Inc | Stock-Other | 0.32% | — | — | |
| 36 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.31% | — | -0.80% | |
| 37 | ANNX | Annexon Inc | Stock-Other | 0.31% | — | -80.49% | |
| 38 | FATE | Fate Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 39 | NKTX | Nkarta Inc | Stock-Other | 0.22% | — | — | |
| 40 | NUVB | Nuvation Bio Inc | Stock-Other | 0.20% | — | -68.61% | |
| 41 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.15% | — | — | |
| 42 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.14% | — | — | |
| 43 | ✓ | Stock-Other | 0.12% | — | +15.30% | ||
| 44 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.10% | — | — |
According to official SEC Form 13F filings, Octagon Capital Advisors LP reported a total U.S. public equity portfolio value of $1.1B across 44 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including APLSUSD, INSM, DNTH) accounted for 28.4% of total reported equity market value during Q2 2024.
During Q2 2024, Octagon Capital Advisors LP's top holdings by market value included APLSUSD (19.5%)、INSM (9.5%)、DNTH (7.1%). The largest single position, APLSUSD, represented 19.5% of total portfolio value.
In Q2 2024, Octagon Capital Advisors LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.